Tracing the effect of the melanocortin-4 receptor pathway in obesity: study design and methodology of the TEMPO registry
Received 21 December 2018
Accepted for publication 8 May 2019
Published 5 June 2019 Volume 2019:12 Pages 87—93
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Martin H. Maurer
Ihuoma Eneli,1,2 Jinyu Xu,1 Matthew Webster,3 Amy McCagg,3 Lex Van Der Ploeg,3 Alastair S Garfield,3 Elizabeth Estrada4
1Center for Healthy Weight and Nutrition, Nationwide Children’s Hospital, Columbus, OH, USA; 2Department of Pediatrics, The Ohio State University, Columbus, OH, USA; 3Department of Medical Communications, Rhythm Pharmaceuticals, Inc, Boston, MA, USA; 4Department of Pediatric Endocrinology, University of North Carolina, Chapel Hill, NC, USA
Purpose: The hypothalamic melanocortin-4 receptor (MC4R) pathway, a component of the central melanocortin pathway, regulates energy balance and satiety. Rare genetic disorders of obesity may be characterized by impaired MC4R pathway signaling, which results in early-onset severe obesity and insatiable hunger (hyperphagia). The TEMPO registry (NCT03479437) is a voluntary, prospective, open-ended registry of individuals with rare genetic disorders of obesity due to mutations in genes within the MC4R pathway who have early-onset severe obesity. The objective of the TEMPO registry is to evaluate the burden of rare genetic disorders of obesity on individuals, their parents/caregivers, health care providers, and the health care system.
Patients and methods: Individuals with rare genetic disorders of obesity (adults aged ≥18 years and children and adolescents aged from 2 to 17 years) will be referred by their health care providers or by a genetic screening study. Individuals must meet age- and sex-specific body mass index values that define the clinical criteria for severe obesity and carry selected variants in MC4R or in one of several genes upstream or downstream of the MC4R. Online surveys will be completed by the individual, parent/caregiver, and health care provider at baseline and annually thereafter and will collect data on demographics, results of genetic testing, medical/family history, disease characteristics, resource utilization, eating habits/hunger episodes, social and emotional impacts, and interest in future clinical trial participation.
Conclusions: The TEMPO registry will provide insights into the overall course and disease burden for individuals with rare genetic disorders of obesity. Health care providers may use this resource to improve the identification, diagnosis, and treatment of individuals with rare forms of genetic obesity.
Keywords: Alström syndrome, Bardet-Biedl syndrome, LEPR, PCSK1, POMC, severe obesity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]